Boris Orlov
Keine laufenden Positionen mehr
Karriereverlauf von Boris Orlov
Ehemalige bekannte Positionen von Boris Orlov
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
Innovalve Bio Medical Ltd.
Innovalve Bio Medical Ltd. Medical SpecialtiesHealth Technology Innovalve Bio Medical Ltd. is an Israeli medical device company that specializes in developing catheter-delivered heart valve therapies. Innovalve Bio Medical was founded in 2017 by Boris Orlov and Ehud Raanani, and is currently based in Ramat Gan, IL. The company aims to address the prevalent and progressive disease of Mitral Regurgitation (MR), which affects nearly 1 in 10 people aged 75 and older. MR is a progressive disease that can lead to advanced stages of MR, heart failure, and other complications. Eyal Baror has been the CEO of the company since 2020. | Gründer | 01.01.2017 | - |
Lartim Medical Ltd.
Lartim Medical Ltd. Financial ConglomeratesFinance Lartim Medical Ltd. operates as a development stage company. The company was founded by Boris Orlov in 2008 and is headquartered in Kiryat Shmona, Israel. | Direktor/Vorstandsmitglied | 01.03.2008 | - |
Gründer | 27.10.2009 | - |
Statistik
International
Israel | 3 |
Operativ
Founder | 2 |
Director/Board Member | 1 |
Sektoral
Finance | 2 |
Health Technology | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Private Unternehmen | 2 |
---|---|
Lartim Medical Ltd.
Lartim Medical Ltd. Financial ConglomeratesFinance Lartim Medical Ltd. operates as a development stage company. The company was founded by Boris Orlov in 2008 and is headquartered in Kiryat Shmona, Israel. | Finance |
Innovalve Bio Medical Ltd.
Innovalve Bio Medical Ltd. Medical SpecialtiesHealth Technology Innovalve Bio Medical Ltd. is an Israeli medical device company that specializes in developing catheter-delivered heart valve therapies. Innovalve Bio Medical was founded in 2017 by Boris Orlov and Ehud Raanani, and is currently based in Ramat Gan, IL. The company aims to address the prevalent and progressive disease of Mitral Regurgitation (MR), which affects nearly 1 in 10 people aged 75 and older. MR is a progressive disease that can lead to advanced stages of MR, heart failure, and other complications. Eyal Baror has been the CEO of the company since 2020. | Health Technology |
- Börse
- Insiders
- Boris Orlov
- Erfahrung